The so-called booster dose of the vaccine against Covid-19 continues to provide strong protection to the elderly almost 4 months after the third dose, according to new data released today by the health authorities of Of Britain.
The efficacy of the vaccine (against severe disease requiring hospitalization) for those over 65 years of age, 15 weeks after booster dose estimated at 85%, from 91% which was two weeks after administration of the third doseaccording to the latest Vaccine Surveillance Report in Britain.
These data are the first to be published in the UK regarding the long-term resistance of booster doses of Covid-19 vaccines. The British authorities give a fourth dose to vulnerable age groupsas is the case in other countries (eg Israel), as the world is confronted with the highly contagious Omicron variant of the coronavirus.
Wednesday dose is administered 6 months after Tuesdaywhile considering a broader campaign for the fall.
The report attempts to distinguish between patients who were hospitalized for Covid and those who were hospitalized for another illness and tested positive for routine tests. Patients with respiratory problems were considered, suggesting that their introduction was most likely related to Covid-19.
For people aged 18-64 years, the efficacy of the vaccine against severe disease appears to decline more: 15 weeks after booster dose, calculated at 67% compared to 88% two weeks after the third dose.
However, British health authorities say this is most likely due to the fact that younger people are more likely to be hospitalized for other reasons and also have Covid, creating a misconception that vaccines are less effective.
The report reiterates that protection against the onset of symptoms decreases more dramatically for all age groups: from 60-75% efficacy 2-4 weeks after the booster dose … to 25-40% after 15 weeks.
Vaccines developed mainly by Pfizer / BioNTech, Moderna and AstraZeneca have been given in Britain. The so-called booster dose program, which began in September, includes Pfizer / BioNTech and Moderna formulations.
Follow Skai.gr on Google News
and be the first to know all the news
